Executive summary

Based on the SEER database, this study reported that for Medicare beneficiaries with a first-time diagnosis of prostate cancer, the utilization of IMRT, proton therapy, and SBRT increased 23.62%, 0.74% and 1.61% respectively (p <0.0001) while brachytherapy decreased 17.04% (p <0.0001).

IMRT is the primary mode of treatment. Utilization of brachytherapy decreased significantly despite the efficacy and cost-effectiveness. Cost per beneficiary decreased $340.24 annually (p = 0.0065). Age, registry region, and Gleason score were all associated with expenditures.
 

Top cancer treatments